Skip to main content
OpenTrials
Completed

NCT Number: NCT00586287

Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon

Oral anticoagulation is often initiated in hospitalized patients. Although the therapeutic range of phenprocoumon is narrow, the individual drug demands unfortunately vary greatly between persons. Our group recently developed two dosing algorithms for the initiation of anticoagulation based on clinical predictors such as age, gender, body weight and laboratory values.

The aim of the proposed study is to prospectively evaluate the efficacy and safety of these two algorithms in medical and orthopedic inpatients, as well as in a group of outpatients and possibly in a geriatric collective.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Background:

The presently available oral anticoagulants have a very narrow therapeutic range but the interindividual demands to achieve therapeutic anticoagulation (=loading dose) varies greatly. Overanticoagulation is a major cause of bleeding complications, whereas insufficient anticoagulation is associated with thromboembolic disease and possibly prolonged hospital stay. A model to predict the loading dose with phenprocoumon (Marcoumar®) is therefore highly desirable.

In a retrospective analysis of 300 inpatients (152 medical, 148 orthopedic patients) of the Cantonal Hospital of St. Gallen our group identified clinical predictors for the loading dose of phenprocoumon and two dosing algorithms were developed (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.).

In order to validate the safety and efficacy of these dosing algorithms we plan this prospective interventional study with three equally sized arms: dosing according to algorithm 1, dosing according to algorithm 2 or dosing according to the estimate of the physician (control).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Consecutive inpatients of the internal medicine and the orthopedic surgery department of the Cantonal Hospital of St. Gallen needing new onset oral anticoagulation

Exclusion criteria

  • Patients with prior oral anticoagulation with coumarines within less than 6 weeks,
  • patents, who received vitamin-K supplements within less than one week before the onset of oral anticoagulation,
  • patients with liver cirrhosis other than Child A,
  • pregnant women (pregnancy has to be excluded in women of childbearing age),
  • patients younger than 18 years, and
  • patients unwilling or unable to give informed consent
  • patients with (clinically diagnosed) dementia and
  • persons with insufficient German, French, Italian or English language skills)

Treatment and study plan

Algorithm for phenprocoumon

Other

Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)

Other names: Marcoumar

Phenprocoumon

Drug

Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician

Other names: Marcoumar

Primary outcomes

  1. rate of patients with therapeutic INR levels on day six without anticoagulation-related complications during the loading period

    Time frame: after 30 days

Secondary outcomes

  1. the time-course of the INR-values, the rate of excessive INR-values, defined as INR >3.5 within 10 days, the rate of minor and major bleeding complications, the length of stay, and death within 30 days

    Time frame: 30 days

Sponsors and collaborators

Lead sponsor

Cantonal Hospital of St. Gallen

Other

Registry information

Official study title

Prospective Randomized Trial of a Clinical Algorithm to Predict the Loading Dose of Phenprocoumon

Important dates

Study start
2007
Primary completion
2011
Study completion
2011
First posted
Jan 4, 2008
Registry last updated
Apr 2, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.